転移性肺腺がん治療の世界市場レポート 2025年

転移性肺腺がん治療市場規模は、今後数年間で力強い成長が見込まれます。2029年には複合年間成長率（CAGR）9.9％で66億4,000万米ドルに成長します。予測期間中の成長は、喫煙および環境要因の有病率の上昇、新規薬物療法の承認の増加、新興市場における医療インフラの拡大、個別化医療アプローチの台頭、製薬企業と研究機関の協力関係の拡大に起因すると考えられます。予測期間における主な動向としては、リキッドバイオプシー技術の発展、より良い治療結果を得るための高度な併用療法の開発、標的ドラッグデリバリーシステムの革新、精密治療のためのAI主導型診断の進歩、免疫腫瘍学治療の進歩などが挙げられます。

標的療法の採用拡大が転移性肺腺がん治療市場の成長を牽引すると予想されます。標的療法は、腫瘍の発生や拡大を促進する特定の遺伝子やタンパク質を標的とすることで、薬剤を用いてがんの増殖を阻止するものです。この治療法は、特定の遺伝子変異を標的とするため、その精度の高さから人気を集めており、従来の治療法に比べて副作用が少なく、より効果的な治療結果が得られます。転移性肺腺がんの場合、標的治療はがんの成長を促進する遺伝子変異をブロックすることに焦点を当て、患者の生存期間と生活の質を改善します。例えば、2023年7月、米国遺伝子細胞治療学会（ASGCT）とCitelineは、第II相試験中の遺伝子治療薬の数が5％増加し、2023年第2四半期末までに260に達したと報告しました。標的療法の利用拡大が市場拡大に寄与しています。

転移性肺腺がん治療市場の各社は、長期生存率と患者の転帰を改善するため、特定の遺伝子変異を標的とした化学療法不要の治療法の開発にも注力しています。標的療法や免疫療法など、化学療法を用いない選択肢は、従来の化学療法の厳しい副作用を軽減しながら、がんを効果的に管理することを目指しています。例えば、Johnson & Johnsonは2024年8月、米国食品医薬品局（FDA）が、特定のEGFR遺伝子変異を有する転移性非小細胞肺がん（NSCLC）に対する化学療法を用いない一次治療として、RYBREVANT（amivantamab-vmjw）とLAZCLUZE（lazertinib）の併用を承認したと発表しました。この承認は、オシメルチニブと比較して無増悪生存期間が改善した第3相MARIPOSA試験に基づいています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場 - 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の転移性肺腺がん治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の転移性肺腺がん治療市場：成長率分析
• 世界の転移性肺腺がん治療市場の実績：規模と成長, 2019-2024
• 世界の転移性肺腺がん治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の転移性肺腺がん治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の転移性肺腺がん治療市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• 免疫療法
• 放射線治療
• 世界の転移性肺腺がん治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 静脈内
• 世界の転移性肺腺がん治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん研究センター
• 専門クリニック
• 世界の転移性肺腺がん治療市場：化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラチナ製剤化学療法
• 非プラチナ製剤化学療法
• 併用療法
• 単剤化学療法
• 世界の転移性肺腺がん治療市場：標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 上皮成長因子受容体阻害剤
• 未分化リンパ腫キナーゼ阻害剤
• C-Rosオンコゲン1受容体チロシンキナーゼ阻害剤
• V-Rafマウス肉腫ウイルスがん遺伝子ホモログB1阻害剤
• トランスフェクション中に再配置された阻害剤
• 間葉系上皮移行因子阻害剤
• 神経栄養性トロポミオシン受容体キナーゼ阻害剤
• 世界の転移性肺腺がん治療市場：免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PD-1阻害剤
• PD-L1阻害剤
• CTLA-4阻害剤
• 併用免疫療法
• CAR-T細胞療法（新興）
• 世界の転移性肺腺がん治療市場：放射線治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線治療（EBRT）
• 定位放射線治療（SBRT）
• 強度変調放射線治療（IMRT）
• 陽子線治療

第7章 地域別・国別分析

• 世界の転移性肺腺がん治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の転移性肺腺がん治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 転移性肺腺がん治療市場：競合情勢
• 転移性肺腺がん治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Astellas Pharma Inc.
• Exelixis
• BeiGene Ltd.
• Novocure
• Blueprint Medicines Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 転移性肺腺がん治療市場2029：新たな機会を提供する国
• 転移性肺腺がん治療市場2029：新たな機会を提供するセグメント
• 転移性肺腺がん治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Metastatic lung adenocarcinoma treatment involves medical strategies aimed at managing lung cancer that has spread beyond the lungs. The primary goals are to slow tumor progression, alleviate symptoms, and prolong survival. As a palliative approach, it focuses on improving the quality of life while controlling the advancement of the disease.

The main types of treatment for metastatic lung adenocarcinoma are chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Chemotherapy uses powerful drugs to kill rapidly dividing cancer cells throughout the body. It is often administered intravenously or orally and can be used alone or in combination with other treatments. The primary routes of administration are oral and intravenous, and the treatment is provided by various end-users, including hospitals, cancer research centers, and specialty clinics.

The metastatic lung adenocarcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides metastatic lung adenocarcinoma treatment market statistics, including the metastatic lung adenocarcinoma treatment industry global market size, regional shares, competitors with the metastatic lung adenocarcinoma treatment market share, detailed metastatic lung adenocarcinoma treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic lung adenocarcinoma treatment industry. This metastatic lung adenocarcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic lung adenocarcinoma treatment market size has grown rapidly in recent years. It will grow from$4.13 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to the increasing incidence of lung cancer, the rising demand for targeted therapies, the growing adoption of immunotherapy, higher investments in oncology research, and the increasing awareness about early detection and diagnosis.

The metastatic lung adenocarcinoma treatment market size is expected to see strong growth in the next few years. It will grow to$6.64 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth during the forecast period can be attributed to the rising prevalence of smoking and environmental factors, the increasing approval of novel drug therapies, the expanding healthcare infrastructure in emerging markets, the rise in personalized medicine approaches, and the growing collaborations between pharmaceutical companies and research institutions. Key trends in the forecast period include advancements in liquid biopsy technologies, the development of advanced combination therapies for better outcomes, innovations in targeted drug delivery systems, progress in AI-driven diagnostics for precision treatment, and the advancement of immuno-oncology treatments.

The increasing adoption of targeted therapy is expected to drive the growth of the metastatic lung adenocarcinoma treatment market. Targeted therapy uses drugs to block cancer growth by targeting specific genes or proteins that drive tumor development and spread. This approach is gaining popularity due to its precision, as it targets specific genetic mutations, resulting in more effective treatment outcomes with fewer side effects compared to traditional therapies. For metastatic lung adenocarcinoma, targeted therapy focuses on blocking genetic mutations that fuel cancer growth, improving survival and quality of life for patients. For instance, in July 2023, the American Society of Gene and Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in Phase II trials increased by 5%, reaching 260 by the end of Q2 2023. The growing use of targeted therapies is contributing to the market's expansion.

Companies in the metastatic lung adenocarcinoma treatment market are also focusing on developing chemotherapy-free treatments that target specific genetic mutations to improve long-term survival rates and patient outcomes. Chemotherapy-free options, such as targeted therapy and immunotherapy, aim to manage cancer effectively while reducing the harsh side effects of traditional chemotherapy. For example, in August 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved RYBREVANT (amivantamab-vmjw) in combination with LAZCLUZE (lazertinib) as a first-line, chemotherapy-free treatment for metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. This approval was based on the Phase 3 MARIPOSA study, which showed improved progression-free survival compared to osimertinib.

In January 2024, Bristol Myers Squibb (BMS) acquired Mirati Therapeutics for $4.8 billion to strengthen its cancer treatment portfolio, particularly its targeted therapies for non-small cell lung cancer (NSCLC). The acquisition supports BMS's strategy to expand its oncology pipeline and address unmet needs in cancer care. Mirati Therapeutics specializes in treatments for KRASG12C-mutated NSCLC, a critical mutation that is difficult to treat. This acquisition enhances BMS's ability to offer more precise, targeted treatments for lung cancer patients, further propelling the growth of the metastatic lung adenocarcinoma treatment market.

Major players in the metastatic lung adenocarcinoma treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Exelixis, BeiGene Ltd., Novocure, and Blueprint Medicines Corporation.

North America was the largest region in the metastatic lung adenocarcinoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic lung adenocarcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic lung adenocarcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic lung adenocarcinoma treatment market consists of revenues earned by entities by providing services such as palliative and supportive care services, medical oncology services, diagnostic imaging, multidisciplinary team coordination, patient education, and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic lung adenocarcinoma treatment market also includes sales of tumor-targeted radiopharmaceuticals, anti-angiogenic agents, and bispecific antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Lung Adenocarcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic lung adenocarcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic lung adenocarcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic lung adenocarcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Chemotherapy; Targeted Therapy; Immunotherapy; Radiation Therapy
• 2) By Route of Administration: Oral; Intravenous
• 3) By End-User: Hospitals; Cancer Research Centers; Specialty Clinics
• Subsegments:
• 1) By Chemotherapy Drugs: Platinum-Based Chemotherapy; Non-Platinum Chemotherapy; Combination Therapy; Single-Agent Chemotherapy
• 2) By Targeted Therapy,: Epidermal Growth Factor Receptor Inhibitors; Anaplastic Lymphoma Kinase Inhibitors; C-Ros Oncogene 1 Receptor Tyrosine Kinase Inhibitors; V-Raf Murine Sarcoma Viral Oncogene Homolog B1 Inhibitors; Rearranged During Transfection Inhibitors; Mesenchymal-Epithelial Transition Factor Inhibitors; Neurotrophic Tropomyosin Receptor Kinase Inhibitors
• 3) By Immunotherapy: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors; Combination Immunotherapy; CAR-T Cell Therapy (Emerging)
• 4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiotherapy (SBRT); Intensity-Modulated Radiation Therapy (IMRT); Proton Therapy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic Lung Adenocarcinoma Treatment Market Characteristics

3. Metastatic Lung Adenocarcinoma Treatment Market Trends And Strategies

4. Metastatic Lung Adenocarcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Metastatic Lung Adenocarcinoma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metastatic Lung Adenocarcinoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metastatic Lung Adenocarcinoma Treatment Market Growth Rate Analysis
• 5.4. Global Metastatic Lung Adenocarcinoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metastatic Lung Adenocarcinoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metastatic Lung Adenocarcinoma Treatment Total Addressable Market (TAM)

6. Metastatic Lung Adenocarcinoma Treatment Market Segmentation

• 6.1. Global Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• 6.2. Global Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• 6.3. Global Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Centers
• Specialty Clinics
• 6.4. Global Metastatic Lung Adenocarcinoma Treatment Market, Sub-Segmentation Of Chemotherapy Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platinum-Based Chemotherapy
• Non-Platinum Chemotherapy
• Combination Therapy
• Single-Agent Chemotherapy
• 6.5. Global Metastatic Lung Adenocarcinoma Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epidermal Growth Factor Receptor Inhibitors
• Anaplastic Lymphoma Kinase Inhibitors
• C-Ros Oncogene 1 Receptor Tyrosine Kinase Inhibitors
• V-Raf Murine Sarcoma Viral Oncogene Homolog B1 Inhibitors
• Rearranged During Transfection Inhibitors
• Mesenchymal-Epithelial Transition Factor Inhibitors
• Neurotrophic Tropomyosin Receptor Kinase Inhibitors
• 6.6. Global Metastatic Lung Adenocarcinoma Treatment Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4 Inhibitors
• Combination Immunotherapy
• CAR-T Cell Therapy (Emerging)
• 6.7. Global Metastatic Lung Adenocarcinoma Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Stereotactic Body Radiotherapy (SBRT)
• Intensity-Modulated Radiation Therapy (IMRT)
• Proton Therapy

7. Metastatic Lung Adenocarcinoma Treatment Market Regional And Country Analysis

• 7.1. Global Metastatic Lung Adenocarcinoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metastatic Lung Adenocarcinoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market

• 8.1. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic Lung Adenocarcinoma Treatment Market

• 9.1. China Metastatic Lung Adenocarcinoma Treatment Market Overview
• 9.2. China Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic Lung Adenocarcinoma Treatment Market

• 10.1. India Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic Lung Adenocarcinoma Treatment Market

• 11.1. Japan Metastatic Lung Adenocarcinoma Treatment Market Overview
• 11.2. Japan Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic Lung Adenocarcinoma Treatment Market

• 12.1. Australia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic Lung Adenocarcinoma Treatment Market

• 13.1. Indonesia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic Lung Adenocarcinoma Treatment Market

• 14.1. South Korea Metastatic Lung Adenocarcinoma Treatment Market Overview
• 14.2. South Korea Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic Lung Adenocarcinoma Treatment Market

• 15.1. Western Europe Metastatic Lung Adenocarcinoma Treatment Market Overview
• 15.2. Western Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic Lung Adenocarcinoma Treatment Market

• 16.1. UK Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic Lung Adenocarcinoma Treatment Market

• 17.1. Germany Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic Lung Adenocarcinoma Treatment Market

• 18.1. France Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic Lung Adenocarcinoma Treatment Market

• 19.1. Italy Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic Lung Adenocarcinoma Treatment Market

• 20.1. Spain Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market

• 21.1. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market Overview
• 21.2. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic Lung Adenocarcinoma Treatment Market

• 22.1. Russia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic Lung Adenocarcinoma Treatment Market

• 23.1. North America Metastatic Lung Adenocarcinoma Treatment Market Overview
• 23.2. North America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic Lung Adenocarcinoma Treatment Market

• 24.1. USA Metastatic Lung Adenocarcinoma Treatment Market Overview
• 24.2. USA Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic Lung Adenocarcinoma Treatment Market

• 25.1. Canada Metastatic Lung Adenocarcinoma Treatment Market Overview
• 25.2. Canada Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic Lung Adenocarcinoma Treatment Market

• 26.1. South America Metastatic Lung Adenocarcinoma Treatment Market Overview
• 26.2. South America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic Lung Adenocarcinoma Treatment Market

• 27.1. Brazil Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic Lung Adenocarcinoma Treatment Market

• 28.1. Middle East Metastatic Lung Adenocarcinoma Treatment Market Overview
• 28.2. Middle East Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic Lung Adenocarcinoma Treatment Market

• 29.1. Africa Metastatic Lung Adenocarcinoma Treatment Market Overview
• 29.2. Africa Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic Lung Adenocarcinoma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Metastatic Lung Adenocarcinoma Treatment Market Competitive Landscape
• 30.2. Metastatic Lung Adenocarcinoma Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic Lung Adenocarcinoma Treatment Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. Novartis AG
• 31.6. GlaxoSmithKline plc
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Eli Lilly and Company
• 31.9. Amgen Inc.
• 31.10. Boehringer Ingelheim International GmbH
• 31.11. Astellas Pharma Inc.
• 31.12. Exelixis
• 31.13. BeiGene Ltd.
• 31.14. Novocure
• 31.15. Blueprint Medicines Corporation

32. Global Metastatic Lung Adenocarcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Lung Adenocarcinoma Treatment Market

34. Recent Developments In The Metastatic Lung Adenocarcinoma Treatment Market

35. Metastatic Lung Adenocarcinoma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Metastatic Lung Adenocarcinoma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metastatic Lung Adenocarcinoma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metastatic Lung Adenocarcinoma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer